Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Novavax, Inc (NASDAQ: NVAX) closed at $7.56 in the last session, down -1.69% from day before closing price of $7.69. In other words, the price has decreased by -$1.69 from its previous closing price. On the day, 2.26 million shares were traded. NVAX stock price reached its highest trading level at $7.715 during the session, while it also had its lowest trading level at $7.48.
Ratios:
We take a closer look at NVAX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 0.97 and its Current Ratio is at 0.98.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on February 28, 2025, initiated with a Buy rating and assigned the stock a target price of $19.
On July 30, 2024, JP Morgan Downgraded its rating to Underweight which previously was Neutral but kept the price unchanged to $8.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 13 ’24 when King Rachel K. sold 4,150 shares for $9.02 per share. The transaction valued at 37,435 led to the insider holds 14,770 shares of the business.
YOUNG JAMES F sold 5,400 shares of NVAX for $43,200 on Dec 31 ’24. The Director now owns 51,760 shares after completing the transaction at $8.00 per share. On Dec 24 ’24, another insider, YOUNG JAMES F, who serves as the Director of the company, sold 4,600 shares for $8.48 each. As a result, the insider received 39,008 and left with 57,160 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVAX now has a Market Capitalization of 1236891648 and an Enterprise Value of 556335104. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.78. Its current Enterprise Value per Revenue stands at 0.816 whereas that against EBITDA is -3.033.
Stock Price History:
The Beta on a monthly basis for NVAX is 3.11, which has changed by 0.5587629 over the last 52 weeks, in comparison to a change of 0.10063088 over the same period for the S&P500. Over the past 52 weeks, NVAX has reached a high of $23.86, while it has fallen to a 52-week low of $3.81. The 50-Day Moving Average of the stock is -8.02%, while the 200-Day Moving Average is calculated to be -29.66%.
Shares Statistics:
According to the various share statistics, NVAX traded on average about 4.31M shares per day over the past 3-months and 3278510 shares per day over the past 10 days. A total of 160.42M shares are outstanding, with a floating share count of 146.57M. Insiders hold about 8.87% of the company’s shares, while institutions hold 59.79% stake in the company. Shares short for NVAX as of 1741910400 were 37551429 with a Short Ratio of 9.11, compared to 1739491200 on 35447513. Therefore, it implies a Short% of Shares Outstanding of 37551429 and a Short% of Float of 29.09.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
A comprehensive evaluation of Novavax, Inc (NVAX) is underway, with the input of 5.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.2, with high estimates of $0.64 and low estimates of -$0.36.
Analysts are recommending an EPS of between $2.69 and -$1.3 for the fiscal current year, implying an average EPS of -$0.24. EPS for the following year is $0.53, with 6.0 analysts recommending between $2.49 and -$1.15.
Revenue Estimates
According to 4 analysts, the current quarter’s revenue is expected to be $67.7M. It ranges from a high estimate of $106.4M to a low estimate of $31.9M. As of the current estimate, Novavax, Inc’s year-ago sales were $93.86MFor the next quarter, 4 analysts are estimating revenue of $150.3M. There is a high estimate of $191.9M for the next quarter, whereas the lowest estimate is $77M.
A total of 7 analysts have provided revenue estimates for NVAX’s current fiscal year. The highest revenue estimate was $1.1B, while the lowest revenue estimate was $325M, resulting in an average revenue estimate of $503.95M. In the same quarter a year ago, actual revenue was $682.16MBased on 6 analysts’ estimates, the company’s revenue will be $521.65M in the next fiscal year. The high estimate is $888.6M and the low estimate is $320.58M.
